Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDR | P35968 | 13/20 | 0.41 |
| ▸ | CYP3A4 | P08684 | 7/20 | 0.40 |
| ▸ | CYP2D6 | P10635 | 7/20 | 0.40 |
| ▸ | CYP2C9 | P11712 | 7/20 | 0.40 |
| ▸ | CYP2C19 | P33261 | 7/20 | 0.40 |
| ▸ | RIPK1 | Q13546 | 2/20 | 0.36 |
| ▸ | MLKL | Q8NB16 | 2/20 | 0.36 |
| ▸ | RIPK3 | Q9Y572 | 2/20 | 0.36 |
| ▸ | AURKA | O14965 | 1/20 | 0.36 |
| ▸ | CDK1 | P06493 | 2/20 | 0.34 |
| ▸ | MTOR | P42345 | 1/20 | 0.34 |
| ▸ | SMG1 | Q96Q15 | 1/20 | 0.34 |
| ▸ | VCP | P55072 | 1/20 | 0.34 |
| ▸ | IKBKB | O14920 | 1/20 | 0.33 |
| ▸ | CCNT1 | O60563 | 1/20 | 0.33 |
| ▸ | CCNB1 | P14635 | 1/20 | 0.33 |
| ▸ | CDK9 | P50750 | 1/20 | 0.33 |
| ▸ | SYK | P43405 | 2/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6415740 | 0.89 | KDR (0.33) | KDRCYP3A4CYP2D6CYP2C9CYP2C19 | |
| SCHEMBL6417723 | 0.88 | CFD (0.34) | KDRSYK | |
| SCHEMBL5315338 | 0.87 | EPHB4 (0.38) | KDR | |
| SCHEMBL5310133 | 0.87 | EPHB4 (0.38) | KDR | |
| SCHEMBL6431694 | 0.86 | KDR (0.40) | KDRCYP3A4CYP2D6CYP2C9CYP2C19 | |
| SCHEMBL6431700 | 0.85 | KDR (0.40) | KDRCYP3A4CYP2D6CYP2C9CYP2C19 | |
| SCHEMBL5259529 | 0.81 | ACACB (0.36) | CYP3A4CYP2C9 | |
| SCHEMBL6415735 | 0.75 | MAPK14 (0.33) | KDRCYP3A4CYP2D6CYP2C9CYP2C19 | |
| SCHEMBL6421369 | 0.75 | EGLN2 (0.36) | CYP2C19 | |
| SCHEMBL5312144 | 0.75 | CFD (0.35) | KDRSYK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050288502-A1 | Substituted heterocyclic compounds and methods of use | AMGEN, INC. | 2005-12-29 | — | — | US | claimed |
| US-20050288502-A1 | Substituted heterocyclic compounds and methods of use | AMGEN, INC. | 2005-12-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050288502-A1 | Substituted heterocyclic compounds and methods of use | MYLK2, IAPP, MAPT | KDR 218/4885CYP3A4 864/4885CYP2D6 2044/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.